Alemtuzumab

Alemtuzumab, a monoclonal antibody, is a targeted immunotherapy drug that selectively depletes specific immune cells known as T and B lymphocytes. It is used primarily in the treatment of certain autoimmune disorders, such as multiple sclerosis, and for specific types of cancer, such as chronic lymphocytic leukemia. By selectively targeting and eliminating these specific immune cells, Alemtuzumab helps to reduce inflammation and immune response, providing relief for autoimmune symptoms and suppressing the growth of cancerous cells. The medication is typically administered through intravenous infusion and requires close monitoring by healthcare professionals due to its potential side effects.